We encourage you to republish this article online and in print, it’s free under our creative commons attribution license, but please follow some simple guidelines:
  1. You have to credit our authors.
  2. You have to credit SciDev.Net — where possible include our logo with a link back to the original article.
  3. You can simply run the first few lines of the article and then add: “Read the full article on SciDev.Net” containing a link back to the original article.
  4. If you want to also take images published in this story you will need to confirm with the original source if you're licensed to use them.
  5. The easiest way to get the article on your site is to embed the code below.
For more information view our media page and republishing guidelines.

The full article is available here as HTML.

Press Ctrl-C to copy

Science has made substantial progress in extending the survival of people with HIV and reducing the transmission of the virus from mothers to their children. But transferring concepts for HIV vaccines into clinical application has lagged behind.

In this article, Richard D. Klausner, head of the Bill & Melinda Gates Foundation, and colleagues, argue that there is an urgent need to create and to evaluate systematically more candidate vaccines. The rate of development of new HIV vaccine candidates also needs to be accelerated, they say.

They propose the creation of a series of coordinated 'HIV Vaccine Development Centers', each of which would have the critical mass, focus and scientific expertise needed to advance the rapid and systematic development of a particular HIV vaccine approach.

Link to Science article

Reference: Science 300, 2036 (2003)

Related topics